Tucidinostat
Tucidinostat (INN, also known as chidamide and sold under the brand names Epidaza and Hiyasta) is a histone deacetylase inhibitor (HDI) developed in China. It was also known as HBI-8000. It is a benzamide HDI and inhibits Class I HDAC1, HDAC2, HDAC3, as well as Class IIb HDAC10. Tucidinostat is approved by the Chinese FDA for relapsed or refractory peripheral T-cell lymphoma (PTCL) and has orphan drug status in Japan. In Japan, it was approved for relapsed or refractory adult T-cell leukemia-lymphoma (ATLL) treatment in June 2021. Tucidinostat is being researched as a treatment for pancreatic cancer. However, it is not US FDA The United States Food and Drug Administration (FDA or US FDA) is a federal agency of the Department of Health and Human Services. The FDA is responsible for protecting and promoting public health through the control and supervision of food ... approved for the treatment of pancreatic cancer. References {{HDAC inhibitors Histone deacetylas ...
[...More Info...]       [...Related Items...]     OR:     [Wikipedia]   [Google]   [Baidu]